Yahoo Finance 
Global Human Recombinant DNA Market Analysis Report 2022-2027 Featuring Abbvie, Alexion Pharmaceuticals, Amgen, Eli Lilly, Merck & Co, Sanofi, & Takeda Pharmaceutical
Global Human Recombinant DNA Market
Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "Human Recombinant DNA: Global Markets" report has been added to ResearchAndMarkets.com's offering.
This report highlights the current and future market potential for human recombinant DNA and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, trends and key players in the market.
The report also provides market projections from 2022 through 2027. An in-depth discussion of strategic alliances, industry structures, competitive dynamics, and market forces are also provided.
Recombinant DNA technology (RDT) is essential for improving health conditions, primarily by developing new vaccines and pharmaceuticals. The treatment strategies are improved by developing diagnostics kits, monitoring devices and new therapeutic approaches. Additionally, many other industries such as agriculture are benefiting from the research conducted on genetically modified organisms (GMO), for example microorganisms that are considered clean fuel producers and bio degraders.
Advances in oncology research for discovering underlying molecular mechanisms of cancerous cells to develop novel therapeutics is benefitting the market. The rising number of advanced cancer cases worldwide has significantly increased the need for developing DNA damage-response drugs. These drugs can improve cancer survival by providing a selective and well-tolerated treatment approach.
Regulatory approvals that delay product marketing can adversely impact manufacturer revenues. Similarly, a delay in post-approval of a drug product for another therapeutic indication increases clinical trial costs and potentially affects the labeling and approval status of currently marketed products.
Report Includes
Estimation of the market size and analyses of global market trends, with data from 2020, 2021 with projections of compound annual growth rates (CAGRs) through 2026
Highlights of the market potential for human recombinant DNA, based on product, application, and region
Coverage of history and future of human recombinant DNA, and latest technological advancements of the industry
Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
Coverage of regulatory landscape, product recalls, pipeline products, and discussion on future perspective, strategies, and developments of the industry
Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and a relevant patent analysis
Company profiles of major players within the industry AbbVie Inc., Amgen Inc., Eli Lilly, Sanofi
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Overview
Homologous Recombination (Hr)
Targets for Cancer Therapy
Chapter 4 Impact of Covid-19 Pandemic
Chapter 5 Market Dynamics
Market Drivers
Increasing Incidences of Chronic Diseases
Growing Aging Population
Advancements in Manufacturing Technologies
Market Restraints
Price Controls
Entry of Biosimilars
Opportunities
Untapped Potential in Emerging Markets
Chapter 6 Market Breakdown by Product Type
Human Protein Replacements
Market Size and Forecast
Therapeutic Agents for Human Diseases
Market Size and Forecast
Vaccines
Types of Vaccines
Market Size and Forecast
Chapter 7 Market Breakdown by End-user
Biotechnology and Pharmaceutical Industry
Market Size and Forecast
Research Laboratories and Academic Institutes
Market Size and Forecast
Chapter 8 Market Breakdown by Region
Global Market by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 9 Competitive Landscape
Overview
Chapter 10 Company Profiles
Abbvie Inc.
Alexion Pharmaceuticals
Amgen Inc.
Eli Lilly
Merck & Co. Inc.
Sanofi S.A.
Takeda Pharmaceutical Co Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/bzob5z
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
